Search

Your search keyword '"Grande, C."' showing total 973 results
Start Over Author "Grande, C."
973 results on '"Grande, C."'

12. Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO.

Author

Martín García‐Sancho, A., Baile, M., Rodríguez, G., Dlouhy, I., Sancho, J. M., Jarque, I., González‐Barca, E., Salar, A., Espeso, M., Grande, C., Bergua, J., Montes‐Moreno, S., Redondo, A., Enjuanes, A., Campo, E., López‐Guillermo, A., and Caballero, D.

Subjects
DIFFUSE large B-cell lymphomas, LENALIDOMIDE, STEM cell transplantation, AUTOTRANSPLANTATION
Abstract

Summary: Diffuse large B‐cell lymphoma (DLBCL) patients with relapsed or refractory (RR) disease have poor outcomes with current salvage regimens. We conducted a phase 2 trial to analyse the safety and efficacy of adding lenalidomide to R‐ESHAP (LR‐ESHAP) in patients with RR DLBCL. Subjects received 3 cycles of lenalidomide 10 mg/day on days 1–14 of every 21‐day cycle, in combination with R‐ESHAP at standard doses. Responding patients underwent autologous stem‐cell transplantation (ASCT). The primary endpoint was the overall response rate (ORR) after 3 cycles. Centralized cell‐of‐origin (COO) classification was performed. Forty‐six patients were included. The ORR after LR‐ESHAP was 67% (35% of patients achieved complete remission). Patients with primary refractory disease (n = 26) had significantly worse ORR than patients with non‐refractory disease (54% vs. 85%, p = 0.031). No differences in response rates according to the COO were observed. Twenty‐eight patients (61%) underwent ASCT. At a median follow‐up of 41 months, the estimated 3‐year PFS and OS were 42% and 48%, respectively. The most common grade ≥3 adverse events were thrombocytopenia (70% of patients), neutropenia (67%) and anaemia (35%). There were no treatment‐related deaths during LR‐ESHAP cycles. In conclusion, LR‐ESHAP is a feasible salvage regimen with promising efficacy results for patients with RR DLBCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS

Author

Jiménez-Ubieto, A., primary, Poza Santaella, M., additional, Martin, A., additional, Heredia, Y., additional, Dorado, S., additional, Figaredo, G., additional, Rufian, L., additional, Rodriguez, A., additional, Sarandeses, P., additional, Baumann, T., additional, Grande, C., additional, Bárcena, C., additional, Martinez-Lopez, J., additional, Rosa, J.-M., additional, Rapado, I., additional, Ayala, R., additional, Gallardo, M., additional, Sánchez, R., additional, Carrillo, J., additional, Calbacho, M., additional, Parrilla, L., additional, Juarez, A., additional, Mollejo, M., additional, Casado, L. F., additional, Wang, C., additional, Rodriguez, M., additional, De Toledo, P., additional, and Barrio, S., additional

Published
2022
Full Text
View/download PDF

27. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL

Author

Zinzani, P. L., primary, Ansell, S. M., additional, Bosch, F., additional, Friedberg, J. W., additional, Marolleau, J. P., additional, Arcaini, L., additional, Garcia-Sanz, R., additional, Gopal, A. K., additional, Grande, C., additional, Merryman, R., additional, Pinto, A., additional, Smith, S. D., additional, Villasboas, J. C., additional, Wallace, D., additional, Fagerberg, J., additional, Magalhaes, J. G., additional, and Armand, P., additional

Published
2022
Full Text
View/download PDF

28. P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Author

Tamariz-Amador, L.-E., primary, Battaglia, A. M., additional, Maia, C., additional, Zherniakova, A., additional, Guerrero, C., additional, Zabaleta, A., additional, Burgos, L., additional, Botta, C., additional, Fortuño, M.-A., additional, Alignani, D., additional, Blanco, L., additional, Grande, C., additional, Manubens, A., additional, Arguiñano, J.-M., additional, Gomez, C., additional, Perez-Persona, E., additional, Olazabal, I., additional, Oiartzabal, I., additional, Panizo, C., additional, Prosper, F., additional, San Miguel, J. F., additional, Rodriguez-Otero, P., additional, Martín-Sánchez, E., additional, Paiva, B., additional, and ASOVASNA, A. V.-N. H.-H., additional

Published
2022
Full Text
View/download PDF

30. Repeat cryoablation as a redo procedure for atrial fibrillation ablation: Is it a good choice?

Author

Alvarez-Ortega, C, primary, Solorzano, C, additional, Barrera, A, additional, Toquero, J, additional, Martinez-Alday, JD, additional, Grande, C, additional, Rodriguez, A, additional, Garcia-Alberola, A, additional, Perez, L, additional, Ferrero, A, additional, Hernandez, J, additional, Cozar, R, additional, Cano, O, additional, Trucco, E, additional, and Peinado, R, additional

Published
2022
Full Text
View/download PDF

34. ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Búa, Beatriz Rey, primary, Ubieto, A Jiménez, additional, Blanco, JJ Sánchez, additional, Abrisqueta, P, additional, Gutiérrez, A, additional, Páyez, A Ramírez, additional, Giné, E, additional, Etxetxipia, I Zeberio, additional, Terol, MJ, additional, de la Cruz, F, additional, Andreu, R, additional, Ramirez, MJ, additional, de la Fuente, A, additional, Viguria, MC, additional, Peñarrubia, MJ, additional, Grande, C, additional, Barrigón, MD Caballero, additional, and García-Sancho, A Martín, additional

Published
2021
Full Text
View/download PDF

35. Poster: ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Búa, Beatriz Rey, primary, Ubieto, A Jiménez, additional, Blanco, JJ Sánchez, additional, Abrisqueta, P, additional, Gutiérrez, A, additional, Páyez, A Ramírez, additional, Giné, E, additional, Etxetxipia, I Zeberio, additional, Terol, MJ, additional, Cruz, F de la, additional, Andreu, R, additional, Ramirez, MJ, additional, Fuente, A de la, additional, Viguria, MC, additional, Peñarrubia, MJ, additional, Grande, C, additional, Barrigón, MD Caballero, additional, and García-Sancho, A Martín, additional

Published
2021
Full Text
View/download PDF

36. Overlapping prison/community tuberculosis outbreaks in Costa Rica revealed by alternative analysis of suboptimal material

Author

Jbara S, Herranz M, Sola-Campoy PJ, Rodríguez-Grande C, Chiner-Oms Á, Comas I, Muñoz P, García de Viedma D, and Pérez-Lago L

Subjects
low quality DNA, outbreak, tuberculosis, surveillance, epidemiology, prisons
Abstract

Costa Rica has a low incidence of tuberculosis. Thus, identifying transmission hotspots is key to implement interventions. A tuberculosis outbreak was suspected in a prison in Costa Rica. Given the suboptimal quality of the samples received in our laboratory in Madrid, we applied alternative schemes for their analysis. In the first scheme, we bypassed the standard approach of applying systematic mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) and used a strain-specific polymerase chain reaction (PCR) that allowed identifying a cluster involving six cases (C1). The second scheme followed the canonical MIRU-VNTR path coupled with a whole-genomic amplification step, by which a second unsuspected overlapping cluster (C2), was detected in the same prison. These findings justified the implementation of a surveillance programme adapted to local resources based on a tailored multiplex allele-specific oligonucleotide (ASO)-PCR targeting C1 and C2. Presence of the C2 strain at a different prison was determined. ASO-PCR was applied extensively and alerted to the active circulation of one of the strains within and beyond prisons. Our study shows that alternative methodological strategies may provide useful data in settings with lack of resources for performing systematic standard molecular epidemiology programmes and/or with suboptimal material for analysis.

Published
2021

37. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients >= 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Author

Sancho, JM, Fernandez-Alvarez, R, Gual-Capllonch, F, Gonzalez-Garcia, E, Grande, C, Gutierrez, N, Penarrubia, MJ, Batlle-Lopez, A, Gonzalez-Barca, E, Guinea, JM, Gimeno, E, Penalver, FJ, Fuertes, M, Bastos, M, Hernandez-Rivas, JA, Moraleda, JM, Garcia, O, Sorigue, M, and Martin, A

Subjects
liposomal doxorubicin, N-terminal pro-B-type natriuretic peptide, troponin, cardiotoxicity, diffuse large B-cell lymphoma
Abstract

The use of non-pegylated liposomal doxorubicin (Myocet(R)) in diffuse large B-cell lymphoma (DLBCL) has been investigated in retrospective and single-arm prospective studies. This was a prospective phase 2 trial of DLBCL patients >= 60 years old with left ventricular ejection fraction (LVEF) >= 55% randomized to standard R-CHOP or investigational R-COMP (with Myocet(R) instead of conventional doxorubicin). The primary end point was to evaluate the differences in subclinical cardiotoxicity, defined as decrease in LVEF to = 3) and in four R-COMP patients (five episodes, all grade 1-2). No significant differences in efficacy were observed. In conclusion, R-COMP is a feasible immunochemotherapy schedule for DLBCL patients >= 60 years, with similar efficacy to R-CHOP. However, the use of non-pegylated doxorubicin instead of conventional doxorubicin was not associated with less early cardiotoxicity, although some reduced cardiac safety signals were observed.

Published
2021

38. Prospective practice survey of management of cetuximab-related skin reactions

Author

Lugtenberg, R.T., Boers-Doets, C.B., Witteveen, P.O., Herpen, C.M.L. van, Wymenga, A.N., Groot, J.W.B. de, Hoeben, A., Grande, C. Del, Doorn, B. van, Koldenhof, J.J., Driessen, C.M.L., Gelderblom, H., Lugtenberg, R.T., Boers-Doets, C.B., Witteveen, P.O., Herpen, C.M.L. van, Wymenga, A.N., Groot, J.W.B. de, Hoeben, A., Grande, C. Del, Doorn, B. van, Koldenhof, J.J., Driessen, C.M.L., and Gelderblom, H.

Abstract

Item does not contain fulltext, PURPOSE: Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/metastatic (R/M) or locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) patients treated with cetuximab. METHODS: An open-label, prospective observational study conducted in the Netherlands. The occurrence of skin reactions and the care and management options taken were documented for 16 weeks, starting from the first administration of cetuximab. RESULTS: A total of 103 patients were included in 7 hospitals. 38 patients (37%) developed a grade ≥ 2 skin reaction. Eighty-six patients could be analysed for the primary endpoint (73.3% males, mean age 62.4 years, n = 44 LA SCCHN, n = 16 R/M SCCHN, n = 26 mCRC). The most frequently used skin products at some point during the observation period were moisturizing products (70%), systemic antibiotics (64%), topical antibiotics (58%), lipid-regenerating (28%) and other topical products (28%). The overall use of products gradually increased from baseline to week 6-10, reducing by week 16. Hospital protocols were the primary reason (> 50%) for choice of the skincare products and medications. CONCLUSION: A variety of skin care products and antibiotics were commonly used. Only few patients developed severe cutaneous reactions. For patients, the occurrence of skin reactions did not influence their willingness to continue cetuximab therapy.

Published
2021

39. Prospective practice survey of management of cetuximab-related skin reactions

Author

MS Medische Oncologie, Cancer, Lugtenberg, R T, Boers-Doets, C B, Witteveen, P O, van Herpen, C M L, Wymenga, A N M, de Groot, J W B, Hoeben, A, Del Grande, C, van Doorn, B, Koldenhof, J J, Driessen, C M L, Gelderblom, H, MS Medische Oncologie, Cancer, Lugtenberg, R T, Boers-Doets, C B, Witteveen, P O, van Herpen, C M L, Wymenga, A N M, de Groot, J W B, Hoeben, A, Del Grande, C, van Doorn, B, Koldenhof, J J, Driessen, C M L, and Gelderblom, H

Published
2021

42. UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Búa, B. Rey, primary, Jiménez‐Ubieto, A., additional, Blanco, J. J. Sánchez, additional, Abrisqueta, P., additional, Gutiérrez, A., additional, Ramírez‐Páyer, Án., additional, Giné, E., additional, Etxetxipia, I. Zeberio, additional, Terol, M. José, additional, Cruz, F. de la, additional, Andreu, R., additional, Ramírez, M., additional, Fuente, A. de la, additional, Viguria, M., additional, Peñarrubia, M., additional, Grande, C., additional, Montes‐Moreno, S., additional, Barrigón, M. D. Caballero, additional, and García‐Sancho, A. Martín, additional

Published
2021
Full Text
View/download PDF

45. La producción animal en Iztapalapa

Author

Hermenegildo Losada C., José Cortés Z., Daniel Grande C., and Guillermina Hernández M.

Subjects
Anthropology, GN1-890, Political science (General), JA1-92, Social sciences (General), H1-99
Abstract

Resumen

Published
1992

50. Prospective practice survey of management of cetuximab-related skin reactions

Author

Lugtenberg, R. T., primary, Boers-Doets, C. B., additional, Witteveen, P. O., additional, van Herpen, C. M. L., additional, Wymenga, A. N. M., additional, de Groot, J. W. B., additional, Hoeben, A., additional, del Grande, C., additional, van Doorn, B., additional, Koldenhof, J. J., additional, Driessen, C. M. L., additional, and Gelderblom, H., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results